The global large-molecule drug discovery outsourcing market was valued at an estimated USD 3.1 billion in 2025 and is projected to reach USD 6.5 billion by 2033, expanding at a 9.7% compound annual growth rate from 2026 to 2033. The ResearchAndMarkets.com report links growth to rising demand for biologics, increasingly complex development pipelines, artificial intelligence adoption, cost efficiency and shorter development timelines. Pharmaceutical and biotechnology companies are outsourcing work across target identification, screening, validation, lead optimization and preclinical development, while seeking CROs with expertise in bioassay development, structural biology, functional screening, protein engineering and high-throughput screening. The report covers workflows, services, therapeutic areas, end uses and regional markets, with opportunities identified across North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa.